Ciclosporin ophthalmic - Santen SAS

Drug Profile

Ciclosporin ophthalmic - Santen SAS

Alternative Names: Ciclosporin - Santen SAS; Cyclokat; Ikervis; Nova 22007; Vekacia; Verkazia

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novagali Pharma
  • Developer Santen Pharmaceutical; Santen S.A.S.
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Allergic conjunctivitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes
  • Preregistration Allergic conjunctivitis

Most Recent Events

  • 24 Jul 2017 Committee for Medicinal Products for HumanUse (CHMP) recommends approval of ciclosporin for Allergic conjunctivitis (In children, In adolescents) in European Union
  • 23 Jul 2017 Preregistration for Allergic conjunctivitis (In adolescents, In children) in European Union (Ophthalmic) before July 2017
  • 23 Nov 2016 Launched for Dry eyes (In adults) in France (Ophthalmic) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top